Thailand's Medical Cannabis Export Market in 2026: What the Data Actually Shows

The narrative around Thailand as a global medical cannabis export hub has outrun the data for several years. In 2026, the data is beginning to catch up, and the picture it presents is more nuanced than either the optimists or the skeptics have described. This article focuses on what is actually verifiable rather than what is being projected or pitched.

The Compliance Landscape: A Narrow Field

As of February 13, 2026, DTAM reported 217 GACP-certified farms across Thailand. For context, there are over 11,800 legacy-licensed operators in the cannabis space. That means less than 2% of operators hold the minimum domestic certification required to legally supply cannabis flower for export. For international buyers conducting supplier due diligence, this makes genuinely certified Thai sourcing partners scarce and commercially valuable. The bottleneck in the Thai medical cannabis export supply chain is not cultivation capacity or product quality: it is certified, auditable compliance.

The number is growing. In late 2025, DTAM data cited by multiple industry sources indicated approximately 149 GACP-certified farms. By February 13, 2026, that figure had risen to 217, an increase of 68 farms in roughly ten weeks. The trajectory is positive, but the absolute number remains small relative to the scale of international buyer demand for compliant Thai product.

Export Volume: Growing From a Low Base

Thai medical cannabis exports have grown year-on-year since the first reported commercial export shipments in late 2022 and early 2023. Absolute volumes remain modest relative to government projections and the figures frequently cited at industry conferences. Germany remains the largest single destination market, driven by the scale of its liberalized prescription market following the April 2024 partial legalization under CanG. Australia is a significant destination, though import volumes are constrained by TGA regulatory requirements that favor established sourcing relationships and GMP-certified product.

Price Dynamics

Thai flower export prices have faced downward pressure as more licensed cultivators have entered the market and international supply from established producers in Germany, Portugal, and Australia has increased. The premium that early Thai exporters commanded on quality flower has compressed. The market is increasingly differentiating on compliance quality rather than product novelty or origin story. A farm with credible EU-GACP, EU-GMP-aligned documentation, and a track record of clean analytical results can still command premium positioning relative to non-certified competitors.

What the Market Actually Wants

The feedback from active international buyers is consistent: reliable supply, consistent quality, auditable compliance, and predictable logistics. Novel origin stories and competitive pricing are secondary considerations for serious pharmaceutical purchasers who have been burned by supply chain failures before. The compliance infrastructure investment, including GACP, GMP, GDP, and proper analytical testing, is not a regulatory burden for these buyers. It is the minimum entry requirement.

The Realistic Outlook for 2026 and Beyond

Thailand will not become the world's dominant medical cannabis supplier by volume in the near term. The infrastructure, certification timelines, and regulatory complexity make that a medium-term story at best. What Thailand can become, and what serious operators are already building toward, is a respected supplier in the high-compliance, high-value segment of the global market. The operators building toward that outcome are investing in GACP certification, EU-GMP readiness, GDP-compliant logistics, and verified buyer relationships. DeeMED works with operators across this full capability spectrum, from initial compliance gap assessment through active export shipment management.